Citius Oncology reports early LYMPHIR launch traction; 83% of target accounts in formulary review

CITIUS ONCOLOGY, INC.

83% of target accounts have added or are actively progressing LYMPHIR through formulary review.
Market access covering ~80% of covered lives via ~135 health plans; no reimbursement denials reported.
Initial accounts placing repeat orders; sequential growth in orders since launch.
Investigator-led studies: LYMPHIR prior to CAR-T in DLBCL (U Minnesota) and combo with pembrolizumab in solid tumors (UPMC).
Field team onboarding underway; international expansion with distribution agreements in Europe/Middle East.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.